Psychopharmacology and Psychiatry Updates

Епізоди

• 
  Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good 19.08.2026 17хв

  In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 Benzodiazepine Tapering: Key Takeaways From New Guidelines
• 
  Disulfiram Unpacked: Efficacy, Risks, and Liver Safety 14.08.2026 16хв

  In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations
• 
  GLP-1s and Lithium: What Clinicians Need to Know 09.08.2026 11хв

  In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Can GLP-1 Agonists Elevate Lithium Levels?
• 
  Naltrexone for Alcohol Use Disorder: What You Should Know 04.08.2026 13хв

  In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety
• 
  The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life 30.07.2026 16хв

  In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial
• 
  Difficult-to-Treat Depression: First, Second, and Third-Line Strategies 25.07.2026 15хв

  In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines Pharmacologic Management of Difficult-to-Treat Depression: First, Second, and Third Line Options
• 
  Is High-Dose Olanzapine A Clozapine Alternative? 20.07.2026 10хв

  In this episode, we explore whether high-dose olanzapine — beyond the FDA-approved 20 mg ceiling — can be a viable strategy for patients with treatment-resistant schizophrenia when clozapine isn't yet an option. Can pushing the dose bridge the gap between partial response and full remission? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 83 Treatment-Resistant Schizophrenia: Should You Consider High-Dose Olanzapine Instead of Clozapine?
• 
  CANMAT Guidelines: Herbs, Supplements, and Depression 15.07.2026 7хв

  In this episode, we explore what the CANMAT guidelines say about complementary and alternative medicine (CAM) for depression — from St. John's wort to saffron — and how to have evidence-based, collaborative conversations with patients who prefer a more natural approach to treatment. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines Complementary and Alternative Medicine for Depression: CANMAT Recommendations
• 
  Xylazine in the ED: Managing Toxicity 10.07.2026 9хв

  In this episode, we explore the growing threat of xylazine — a veterinary sedative increasingly found in illicit drug supplies — and what clinicians need to know when naloxone simply isn't enough. Dr. David Gorelick breaks down the current evidence on diagnosis, treatment, and the critical gaps that remain. Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 82 Xylazine ("Tranq Dope") Overdose: What Clinicians Should Know
• 
  Choosing the First Step in Depression Treatment: A CANMAT Guide 05.07.2026 18хв

  In this episode, we explore how to select the right initial treatment for depression using the updated CANMAT guidelines. How do severity, patient preference, and treatment availability shape your first clinical move? Dr. Sagar Parikh breaks down the evidence on psychotherapy, antidepressants, and when to combine both. Faculty: Sagar V. Parikh, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines Selecting the Initial Depression Treatment
• 
  After Delirium Clears: When to Deprescribe? 30.06.2026 14хв

  In this episode, we explore the hidden dangers of leaving antipsychotics running long after a hospital delirium episode has resolved. Could a medication prescribed to keep your patient safe in the short term actually be harming them months later — and what does the latest evidence say about stopping it? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 82 Deprescribing Antipsychotics Post-Delirium: Why It Matters
• 
  The Clinician's Guide to Paliperidone & Risperidone LAIs 25.06.2026 15хв

  In this episode, we explore the practical dosing, initiation, and conversion strategies for paliperidone palmitate and risperidone long-acting injectables in schizophrenia. How do you manage a missed six-month injection — reload or continue? Dr. Brian Miller breaks down everything you need to know to prescribe these formulations with confidence. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia LAIs in Practice: Paliperidone & Risperidone
• 
  Antipsychotic Switching: Six Clinical Tips 20.06.2026 12хв

  In this episode, we explore the surprisingly thin evidence base behind antipsychotic switching — one of psychiatry's most common clinical maneuvers. Dr. Oliver Freudenreich breaks down a landmark systematic review and shares six practical tips to help clinicians switch antipsychotics safely and confidently. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 82 Switching Oral Antipsychotics: Six Strategies and Tips
• 
  Mastering Long-Acting Injectables: Aripiprazole & Olanzapine 15.06.2026 11хв

  In this episode, we explore the practical use of long-acting injectable antipsychotics in schizophrenia — specifically aripiprazole and olanzapine formulations. What's the right dose when a patient misses an injection? Dr. Brian Miller breaks down dosing, oral supplementation windows, and dose equivalence for Abilify Maintena, Aristada, and Zyprexa Relprevv. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia LAIs in Practice: Aripiprazole & Olanzapine
• 
  Preventing Relapse: The Role of LAIs in Schizophrenia 05.06.2026 7хв

  In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia Understanding When to Prescribe LAIs
• 
  Could Lithium Play a Role in Preventing Alzheimer's Disease? 31.05.2026 11хв

  In this episode, we explore a striking new Nature study suggesting that lithium deficiency may play a central role in the onset of Alzheimer's disease. Could a simple, overlooked supplement be the key to prevention? Dr. Scott Beach unpacks the science, the promise, and the important caveats. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 81 Lithium Orotate: Breakthrough Treatment for Alzheimer's Disease?
• 
  Managing ADHD in Pregnancy: Weighing Risk versus Risk 26.05.2026 8хв

  In this episode, we explore the nuanced challenge of managing ADHD with stimulant medications during pregnancy. Is stopping the medication always the safer choice — or does untreated ADHD carry risks of its own? Dr. Amanda Koire breaks down the latest evidence to help clinicians make truly informed decisions. Faculty: Amanda Koire, M.D., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know Pregnancy, ADHD, and Stimulants: Making an Informed Choice
• 
  Ondansetron for Negative Symptoms of Schizophrenia 21.05.2026 13хв

  In this episode, we examine a surprising repurposing of ondansetron — a common antiemetic — as a potential adjunctive treatment for the notoriously hard-to-treat negative symptoms of schizophrenia. Could a nausea medication help restore motivation and emotional engagement in your patients with residual symptoms despite stable antipsychotic therapy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 81 Is Ondansetron Effective for Negative Symptoms in Schizophrenia?
• 
  Managing SSRIs During Pregnancy: Myths vs. Evidence 16.05.2026 7хв

  In this episode, we explore how to manage SSRI treatment in pregnant patients — addressing common fears around fetal malformations, medication switching, and neonatal withdrawal. Can stopping an antidepressant actually do more harm than continuing it? Faculty: Amanda Koire, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know SSRI Treatment During Pregnancy: A Clinical Case
• 
  Rethinking Haloperidol's Cardiac Risk 11.05.2026 14хв

  In this episode, we explore a landmark meta-analysis that challenges decades of fear surrounding IV haloperidol and cardiac risk. Could one of medicine's most persistent myths be costing patients their best treatment option for delirium? Dr. Scott Beach breaks down the evidence. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 80 IV Haloperidol: Are Cardiac Safety Concerns Overblown?